Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 6:2010:183461.
doi: 10.4061/2010/183461.

Differentiated thyroid cancer with extrathyroidal extension: prognosis and the role of external beam radiotherapy

Michael A Sia  1 , Richard W Tsang, Tony Panzarella, James D Brierley
Affiliations

Differentiated thyroid cancer with extrathyroidal extension: prognosis and the role of external beam radiotherapy

Michael A Sia et al. J Thyroid Res. .

Abstract

A study was performed to identify variables that affected cause-specific survival (CSS) and local relapse-free rate (LRFR) in patients with differentiated thyroid cancer (DTC) and extrathyroid extension (ETE) and to examine the role of external beam radiotherapy (XRT). Prognostic factors were similar to those found in studies of all patients with DTC. In patients with postoperative gross residual disease treated with radiotherapy, 10-year CSS and LRFR were 48% and 90%. For patients with no residual or microscopic disease, 10-year CSS and LRFR were 92% and 93%. In patients older than 60 years with T3 ETE but no gross residual disease postoperatively there was an improved LRFR at 5 years of 96%, compared to 87.5% without XRT (P = .02). Patients with gross ETE benefit from XRT and there may be a potential benefit in reducing locoregional failure in patients over 60 years with minimal extrathyroidal extension (T3).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cause-specific survival and local recurrence-free rate for patients with differentiated thyroid cancer and extrathyroidal extension. The overall 5- and 10-year cause-specific survivals are 89.8% (SE 0.03%) and 85.4% (SE 0.04%), respectively. The overall 5- and 10-year local relapse-free rates are 92.5% (SE 0.02%) and 91.7% (SE 0.02%), respectively.
Figure 2
Figure 2
Cause-specific survival and local recurrence-free rate for patients with gross residual disease treated with RT; 10-year CSS and LRFR were 48% and 90%, respectively.
Figure 3
Figure 3
Local recurrence-free rate for patients over 45 years of age with T3 tumors treated with and without RT, 96.8% versus 90% at 5 years, respectively, P = .03.
Figure 4
Figure 4
Local recurrence free rate for patients over 60 years of age with T3 tumors treated with and without RT, 96% versus 87.5%, at 5 years, respectively, P = .02.
See this image and copyright information in PMC

References

    1. Lee N, Tuttle M. The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocrine-Related Cancer. 2006;13(4):971–977. - PubMed
    1. British Thyroid Association. Guidelines for the Management of Thyroid Cancer in Adults. London, UK: Royal College of Physicians; 2006.
    1. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109–141. - PubMed
    1. Brierley JD, Asa SL. Thyroid cancer. In: Gospodarowicz MK, O’Sullivan B, Sobin LH, editors. Prognostic Factors in Cancer. Hoboken, NJ, USA: John Wiley & Sons; 2006.
    1. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998;82(2):375–388. - PubMed

LinkOut - more resources